Ketamine effects on brain function - Simultaneous fMRI/EEG during a visual oddball task

NeuroImage

Volumn 58, Issue 2, 2011, Pages 508-525

  Musso, Francesco ^a,b   Brinkmeyer, Jürgen ^a,b   Ecker, Daniel ^c   London, Markus K ^c   Thieme, Giesela ^c   Warbrick, Tracy ^a   Wittsack, Hans Jörg ^b   Saleh, Andreas ^b   Greb, Wolfgang ^c   de Boer, Peter ^d   Winterer, Georg ^a,e  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c FOCUS Clinical Drug Development GmbH   (Germany)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

^e UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Functional biomarker; Ketamine; P300; Pharmacoimaging; Schizophrenia; Simultaneous fMRI EEG

Indexed keywords

KETAMINE;

ADULT; ALTERED STATE OF CONSCIOUSNESS RATING SCALE; ARTICLE; BOLD SIGNAL; BRAIN FUNCTION; CONTROLLED STUDY; DISEASE MODEL; ELECTRODERMAL RESPONSE; ELECTROENCEPHALOGRAM; EVENT RELATED POTENTIAL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SELECTIVE ATTENTION; TASK PERFORMANCE;

ACOUSTIC STIMULATION; ADULT; ANALYSIS OF VARIANCE; BRAIN; CROSS-OVER STUDIES; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EVENT-RELATED POTENTIALS, P300; EVOKED POTENTIALS, AUDITORY; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FUNCTIONAL LATERALITY; GALVANIC SKIN RESPONSE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KETAMINE; MAGNETIC RESONANCE IMAGING; MALE; OXYGEN; PSYCHOMOTOR PERFORMANCE; VISUAL PERCEPTION; YOUNG ADULT;

EID: 80051799656     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.06.045     Document Type: Article

References (115)

1. Allen P., Poliz G., Krakow K., Fish D.R., Lemieux L. Identification of EEG Events in the MR scanner: the problem of pulse artifact and a method for its subtraction. NeuroImage 1998, 8:229-239.
2. Allen P., Josephs O., Turner R. A method for removing imaging artifact from continuous EEG recorded during functional MRI. NeuroImage 2000, 1:230-239.
3. Anderer P., Pascual-Marqui R.D., Semlitsch H.V., Saletu B. Differential effects of normal aging on sources of standard N1, target N1 and target P300 auditory event-related brain potentials revealed by low resolution electromagnetic tomography (LORETA). Electroencephalogr. Clin. Neurophysiol. 1998, 108:160-174.
4. Anderer P., Gruber G., Parapatics S., Woertz M., Miazhynskaia T., Klosch G., Saletu B., Zeitlhofer J., Barbanoj M.J., Danker-Hopfe H., Himanen S.L., Kemp B., Penzel T., Grozinger M., Kunz D., Rappelsberger P., Schlogl A., Dorffner G. An E-health solution for automatic sleep classification according to Rechtschaffen and Kales: validation study of the Somnolyzer 24×7 utilizing the Siesta database. Neuropsychobiology 2005, 51:115-133.
5. Baudena P., Halgren E., Heit G., Clarke J.M. Intracerebral potentials to rare target and distractor auditory and visual stimuli. III. Frontal cortex. Electroencephalogr. Clin. Neurophysiol. 1995, 94:251-264.
6. Behrens T., Woolrich M.W., Smith S. Multi-Testing Using a Fully Subject Null Hypothesis Bayesian Framework: Theory 2003, Human Brain Mapping Meeting, New York City.
7. Borsook D., Becerra L., Hargreaves R. A role for fMRI in optimizing CNS drug development. Nat. Rev. Drug Discovery 2006, 5:411-424.
8. Breier A., Malhotra A.K., Pinals D.A., Weisenfeld N.I., Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am. J. Psychiatry 1997, 154:805-811.
9. Brinkmeyer J., Mobascher A., Warbrick T., Musso F., Wittsack H.J., Saleh A., Schnitzler A., Winterer G. Dynamic EEG-informed fMRI modeling of the pain matrix using 20-ms root mean square segments. Hum. Brain Mapp. 2010, 31:1702-1712.
10. Callicott J.H., Bertolino A., Mattay V.S., Langheim F.J., Duyn J., Coppola R., Goldberg T.E., Weinberger D.R. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb. Cortex 2000, 10:1078-1092.
11. Callicott J.H., Mattay V.S., Verchinski B.A., Marenco S., Egan M.F., Weinberger D.R. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am. J. Psychiatry 2003, 160:2209-2215.
12. Cho R.Y., Ford J.M., Krystal J.H., Laruelle M., Cuthbert B., Carter C.S. Functional neuroimaging and electrophysiology biomarkers for clinical trials for cognition in schizophrenia. Schizophr. Bull. 2005, 31:865-869.
13. Daumann J., Wagner D., Heekeren K., Neukirch A., Thiel C., Gouzoulis-Mayfrank E. Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis. J. Psychopharmacol. 2010, 24:1515-1524.
14. Davies R.J.O., Belt P.J., Roberts S.J., Ali N.J., Stradling J.R. Arterial blood pressure responses to graded transient arousal from sleep in normal humans. J. Appl. Physiol. 1993, 74:1123-1130.
15. Deakin J.F., Lees J., McKie S., Hallak J.E., Williams S.R., Dursun S.M. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch. Gen. Psychiatry 2008, 65:154-164.
16. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs. J. Health Econ. 2003, 22:151-185.
17. Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 1998, 31:80-84.
18. Dittrich A., von Arx S., Staub S. International study on altered states of consciousness (ISASC). Summary of the results. Germ. J. Psych. 1985, 9:319-339.
19. Ehrlichman R.S., Gandal M.J., Maxwell C.R., Lazarewicz M.T., Finkel L.H., Contreras D., Turetsky B.I., Siegel S.J. N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. Neuroscience 2009, 158:705-712.
20. Feng N., Vollenweider F.X., Minder E.L., Rentsch K., Grampp T., Vonderschmitt D.J. Development of gas chromatography-mass spectroscopy method for determination of ketamine in plasma and its application to human samples. Ther. Drug Monit. 1995, 17:95-100.
21. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID - I/P, Version 2.0) 1995, Biometrics Research Department, New York State Psychiatric Institute, New York.
22. Forman S.D., Cohen J.D., Fitzgerald M., Eddy W.F., Mintun M.A., Noll D.C. Improved assessment of significant activation in functional magnetic resonance imaging (fMRI): use of a cluster-size threshold. Magn. Reson. Med. 1995, 33:636-647.
23. Fowles D.C., Christie M.J., Edelberg R., Grings W.W., Lykken D.T., Venables P.H. Committee report. Publication recommendations for electrodermal measurements. Psychophysiology 1981, 18:232-239.
24. Friston K.J., Worsley K.J., Frackowiak R.S.J., Mazziotta J.C., Evans A.C. Assessing the significance of focal activations using their spatial extent. Hum. Brain Mapp. 1994, 1:214-220.
25. Fu C.H., Suckling J., Williams S.C., Andrew C.M., Vythelingum G.N., McGuire P.K. Effects of psychotic state and task demand on prefrontal function in schizophrenia: an fMRI study of overt verbal fluency. Am. J. Psychiatry 2005, 162:485-494.
26. Giard M.H., Perrin F., Echallier J.F., Thevenet M., Froment J.C., Pernier J. Dissociation of temporal and frontal components in the human auditory N1 wave: a scalp current density and dipole model analysis. Electroencephalogr. Clin. Neurophysiol. 1994, 92:238-252.
27. Goldman R.I., Wei C.Y., Philiastides M.G., Gerson A.D., Friedman D., Brown T.R., Sajda P. Single-trial discrimination for integrating simultaneous EEG and fMRI: identifying cortical areas contributing to trial-to-trial variability in the auditory oddball task. NeuroImage 2009, 47:136-147.
28. Grunze H.C., Rainnie D.G., Hasselmo M.E., Barkai E., Hearn E.F., McCarley R.W., Greene R.W. NMDA dependent modulation of CA1 local circuit inhibition. J. Neurosci. 1996, 16:2034-2043.
29. Gur R.E., Turetsky B.I., Loughead J., Snyder W., Kohler C., Elliott M., Pratiwadi R., Ragland J.D., Bilker W.B., Siegel S.J., Kanes S.J., Arnold S.E., Gur R.C. Visual attention circuitry in schizophrenia investigated with oddball event-related functional magnetic resonance imaging. Am. J. Psychiatry 2007, 164:442-449.
30. Halgren E., Baudena P., Clarke J.M., Heit G., Liégeois C., Chauvel P., Musolino A. Intracerebral potentials to rare target and distractor auditory and visual stimuli. I. Superior temporal plane and parietal lobe. Electroencephalogr. Clin. Neurophysiol. 1995, 94:191-220.
31. Halgren E., Baudena P., Clarke J.M., Heit G., Marinkovic K., Devaux B., Vignal J.-P., Biraben A. Intracerebral potentials to rare target and distractor auditory and visual stimuli. II. Medial, lateral and posterior temporal lobe. Electroencephalogr. Clin. Neurophysiol. 1995, 94:229-250.
32. Hill K., Mann L., Laws K.R., Stephenson C.M., Nimmo-Smith I., McKenna P.J. Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr. Scand. 2004, 110:243-256.
33. Holcomb H.H., Lahti A.C., Medoff D.R., Weiler M., Tamminga C.A. Sequential regional cerebral blood flow brain scans using PET with H2(15) O demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology 2001, 25:165-172.
34. Holmes A.P., Blair R.C., Watson J.D., Ford I. Nonparametric analysis of statistical images from functional mapping experiments. J. Cereb. Blood Flow Metab. 1996, 16:7-12.
35. Holsboer F., von Bardeleben U., Steiger A. Effects of intravenous corticotropin-releasing hormone upon sleep-related growth hormone surge and EEG sleep in man. Neuroendocrinology 1988, 48:32-38.
36. Honey R.A.E., Honey G.D., O'Loughlin C., Sharar S.R., Kumaran D., Bullmore E.T., Menon D.K., Donovan T., Lupson V.C., Bisbrown-Chippendale R., Fletcher P.C. Acute ketamine administration alters the brain responses to executive demands in a verbal working memory task: an fMRI study. Neuropsychopharmacology 2004, 29:1203-1214.
37. Honey G.D., Honey R.A.E., O'Loughlin C., Sharar S.R., Kumaran D., Suckling J., Menon D.K., Sleator C., Bullmore E.T., Fletcher P.C. Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: an fMRI study. Cereb. Cortex 2005, 15:749-759.
38. Hong L.E., Summerfelt A., Buchanan R.W., O'Donnell P., Thaker G.K., Weiler M.A., Lahti A.C. Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology 2010, 35:632-640.
39. Javitt D.C. Phenomenology, aetiology and treatment of schizophrenia. Novartis Found Symp. 2008, 289:4-16.
40. Javitt D.C., Spencer K.M., Thaker G.K., Winterer G., Hajós M. Neurophysiological biomarkers for drug development in schizophrenia. Nat. Rev. Drug Discov. 2008, 7:68-83.
41. Jenkinson M., Bannister P., Brady J., Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. NeuroImage 2002, 17:825-841.
42. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
43. Kiehl K.A., Liddle P.F. An event-related functional magnetic resonance imaging study of an auditory oddball task in schizophrenia. Schizophr. Res. 2001, 48:159-171.
44. Kiehl K.A., Laurens K.R., Duty T.L., Forster B.B., Liddle P.F. An event-related fMRI study of visual and auditory oddball tasks. J. Psychophysiol. 2001, 21:221-240.
45. Kiehl K.A., Stevens M.C., Celone K., Kurtz M., Krystal J.H. Abnormal hemodynamics in schizophrenia during an auditory oddball task. Biol. Psychiatry 2005, 57:1029-1040.
46. Kjaer T.W., Law I., Wiltschiøtz G., Paulson O.B., Madsen P.L. Regional cerebral blood flow during light sleep-a H(2)(15)O-PET study. J. Sleep Res. 2002, 11:201-207.
47. Kovacevic N., McIntosh A.R. Groupwise independent component decomposition of EEG data and partial least square analysis. NeuroImage 2007, 35:1103-1112.
48. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA receptor antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
49. Krystal J.H., D'Souza D.C., Mathalon D., Perry E., Belger A., Hoffman R.E. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 2003, 169:215-233.
50. Krystal J.H., Abi-Saab W., Perry E., D'Souza D.C., Liu N., Gueorguieva R., McDougall L., Hunsberger T., Belger A., Levine L., Breier A. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 2005, 179:303-309.
51. Lahti A.C., Holcomb H.H., Medoff D.R., Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995, 6:869-872.
52. Långsjö J.W., Kaisti K.K., Aalto S., Hinkka S., Aantaa R., Oikonen V., Sipilä H., Kurki T., Silvanto M., Scheinin H. Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 2003, 99:614-623.
53. Långsjö J.W., Maksimow A., Salmi E., Kaisti K., Aalto S., Oikonen V., Hinkka S., Aantaa R., Sipilä H., Viljanen T., Parkkola R., Scheinin H. S-ketamine anesthesia increases cerebral blood flow in excess of the metabolic needs in humans. Anesthesiology 2005, 103:258-268.
54. Laurens K.R., Kiehl K.A., Ngan E.T., Liddle P.F. Attention orienting dysfunction during salient novel stimulus processing in schizophrenia. Schizophr. Res. 2005, 75:159-171.
55. Lazarewicz M.T., Ehrlichman R.S., Maxwell C.R., Gandal M.J., Finkel L.H., Siegel S.J. Ketamine modulates theta and gamma oscillations. J. Cogn. Neurosci. 2010, 22:1452-1464.
56. Lee S.Y., Namkoong K., Cho H.H., Song D.H., An S.K. Reduced visual P300 amplitudes in individuals at ultra-high risk for psychosis and first-episode schizophrenia. Neurosci. Lett. 2010, 486:156-160.
57. Liegeois-Chauvel C., Musolino A., Badier J.M., Marquis P., Chauvel P. Evoked potentials recorded from the auditory cortex in man: evaluation and topography of the middle latency components. Electroencephalogr. Clin. Neurophysiol. 1994, 92:204-214.
58. Linden D.E., Prvulovic D., Formisano E., Voellinger M., Zanella F.E., Goebel R., Dierks T. The functional neuroanatomy of target detection: an fMRI study of visual and auditory oddball tasks. Cereb. Cortex 1999, 9:815-823.
59. Littman B.H., Williams S.H. The ultimate model organism: progress in experimental medicine. Nat. Rev. Drug Discov. 2005, 4:631-638.
60. Maccaferri G., Dingledine R. Control of feedforward dendritic inhibition by NMDA receptor-dependent spike timing in hippocampal interneurons. J. Neurosci. 2002, 22:5462-5472.
61. Maksimow A., Särkelä M., Långsjö J.W., Salmi E., Kaisti K.K., Yli-Hankala A., Hinkka-Yli-Salomäki S., Scheinin H., Jääskeläinen S.K. Increase in high frequency EEG activity explains the poor performance of EEG spectral entropy monitor during S-ketamine anesthesia. Clin. Neurophysiol. 2007, 117:1660-1668.
62. Malinowska U., Klekowicz H., Wakarow A., Niemcewicz S., Durka P.J. Fully parametric sleep staging compatible with the classical criteria. Neuroinformatics 2009, 7:245-253.
63. Manoach D.S., Press D.Z., Thangaraj V., Searl M.M., Goff D.C., Halpern E., Saper C.B., Warach S. Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI. Biol. Psychiatry 1999, 45:1128-1137.
64. Manoach D.S., Gollub R.L., Benson E.S., Searl M.M., Goff D.C., Halpern E., Saper C.B., Rauch S.L. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol. Psychiatry 2000, 48:99-109.
65. Mathalon D.H., Ford J.M. The long and the short of it: influence of interstimulus interval on auditory P300 abnormalities in schizophrenia. Clin. Electroencephalogr. 2002, 33:125-135.
66. Mathalon D.H., Hoffman R.E., Watson T.D., Miller R.M., Roach B.J., Ford J.M. Neurophysiological distinction between schizophrenia and schizoaffective disorder. Front. Hum. Neurosci. 2010, 3:70.
67. Menon V., Ford J.M., Lim K.O., Glover G.H., Pfefferbaum A. Combined event-related fMRI and EEG evidence for temporal-parietal cortex activation during target detection. Neuroreport 1997, 8:3029-3037.
68. Mobascher A., Brinkmeyer J., Warbrick T., Musso F., Wittsack H.J., Saleh A., Schnitzler A., Winterer G. Laser-evoked potential P2 single-trial amplitudes covary with the fMRI BOLD response in the medial pain system and interconnected subcortical structures. NeuroImage 2009, 45:917-926.
69. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352.
70. Moores K.A., Clark C.R., Hadfield J.L., Brown G.C., Taylor D.J., Fitzgibbon S.P., Lewis A.C., Weber D.L., Greenblatt R. Investigating the generators of the scalp recorded visuo-verbal P300 using cortically constrained source localization. Hum. Brain Mapp. 2003, 18:53-77.
71. Morey R.A., Inan S., Mitchell T.V., Perkins D.O., Lieberman J.A., Belger A. Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Arch. Gen. Psychiatry 2005, 62:254-262.
72. Morgan C.J., Mofeez A., Brandner B., Bromley L., Curran H.V. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 2004, 29:208-218.
73. Musso F., Brinkmeyer J., Mobascher A., Warbrick T., Winterer G. Spontaneous brain activity and EEG microstates. A novel EEG/fMRI analysis approach to explore resting-state networks. NeuroImage 2010, 52:1149-1161.
74. Newcomer J.W., Krystal J.H. NMDA receptor regulation of memory and behavior in humans. Hippocampus 2001, 11:529-542.
75. Newcomer J.W., Farber N.B., Jevtovic-Todorovic V., Selke G., Melson A.K., Hershey T., Craft S., Olney J.W. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999, 20:106-118.
76. Noh H.J., Bae Y.M., Park S.H., Kim J.G., Kim B., Kim Y.S., Kim S.H., Cho S.I., Woo N.S. The vasodilatory effect of ketamine is independent of the N-methyl-d-aspartate receptor: lack of functional N-methyl-d-aspartate receptors in rat mesenteric artery smooth muscle. Eur. J. Anaesthesiol. 2009, 26:676-682.
77. Northoff G., Richter A., Bermpohl F., Grimm S., Martin E., Marcar V.L., Wahl C., Hell D., Boeker H. NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI. Schizophr. Res. 2005, 72:235-248.
78. Novitskiy N., Ramautar J.R., Vanderperren K., De Vos M., Mennes M., Mijovic B., Vanrumste B., Stiers P., Van den Bergh B., Lagae L., Sunaert S., Van Huffel S., Wagemans J. The BOLD correlates of the visual P1 and N1 in single-trial analysis of simultaneous EEG-fMRI recordings during a spatial detection task. NeuroImage 2011, 54:824-835.
79. Nuechterlein K.H., Dawson M.E. A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr. Bull. 1984, 10:300-312.
80. Nuechterlein K.H., Green M.F., Kern R.S., Baade L.E., Barch D.M., Cohen J.D., Essock S., Fenton W.S., Frese F.J., Gold J.M., Goldberg T., Heaton R.K., Keefe R.S., Kraemer H., Mesholam-Gately R., Seidman L.J., Stover E., Weinberger D.R., Young A.S., Zalcman S., Marder S.R. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 2008, 165:203-213.
81. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 1999, 33:523-533.
82. Oostenveld R., Praamstra P. The five percent electrode system for high-resolution EEG and ERP measurement. Clin. Neurophysiol. 2001, 112:713-719.
83. Oranje B., van Berckel B.N., Kemner C., van Ree J.M., Kahn R.S., Verbaten M.N. The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology 2000, 22:293-302.
84. Oranje B., Gispen de Wied C.C., Westenberg H.G., Kemner C., Verbaten M.N., Kahn R.S. Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude. Int. J. Neuropsychopharmacol. 2009, 12:823-832.
85. Pascual-Marqui R.D. Review of methods for solving the EEG inverse problem. Int. J. Bioelectromagnetism 1999, 1:75-86.
86. Pascual-Marqui R.D. Standardized low-resolution brain electromagnetic tomography (sLORETA): technical details. Methods Find. Exp. Clin. Pharmacol. 2002, 24(Suppl D):5-12.
87. Pascual-Marqui R.D., Michel C.M., Lehmann D. Low resolution electromagnetic tomography: a new method for localizing electrical activity in the brain. Int. J. Psychophysiol. 1994, 18:49-65.
88. Rawlins M.D. Cutting the cost of drug development?. Nat. Rev. Drug Discov. 2004, 3:360-364.
89. Redwine L., Hauger R.L., Gillin J.C., Irwin M. Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans. J. Clin. Endocrinol. Metab. 2000, 85:3597-3603.
90. Rolls E.T., Loh M., Deco G., Winterer G. Computational models of schizophrenia and dopamine modulation in the prefrontal cortex. Nat. Rev. Neurosci. 2008, 9:696-709.
91. Rorden C., Karnath H.O., Bonilha L. Improving lesion-symptom mapping. J. Cogn. Neurosci. 2007, 19:1081-1088.
92. Roth B. The clinical and theoretical importance of EEG rhythms corresponding to states of lowered vigilance. EEG Clin. Neurophysiol. 1961, 13:395-399.
93. Setz C., Arnrich B., Schumm J., La Marca R., Tröster G., Ehlert U. Discriminating stress from cognitive load using a wearable EDA device. IEEE Trans. Inf. Technol. Biomed. 2010, 14:410-417.
94. Sharp F.R., Tomitaka M., Bernaudin M., Tomitaka S. Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?. Trends Neurosci. 2001, 24:330-334.
95. Smith S. Fast robust automated brain extraction. Hum. Brain Mapp. 2002, 17:143-155.
96. Stevens M.C., Calhoun V.D., Kiehl K.A. Hemispheric differences in hemodynamics elicited by auditory oddball stimuli. NeuroImage 2005, 26:782-792.
97. Stone J.M., Abel K.M., Allen M.P., van Haren N., Matsumoto K., McGuire P.K., Fu C.H. Ketamine-induced disruption of verbal self-monitoring linked to superior temporal activation. Pharmacopsychiatry 2010, 44:33-48.
98. Towle V.L., Bolanos J., Suarez D., Tan K., Grzeszcuk R., Levin D.N., Cakmur R., Frank S.A., Spire J.-P. The spatial location of EEG electrodes: locating the best-fitting sphere relative to cortical anatomy. Electroencephalogr. Clin. Neurosci. 1993, 86:1-6.
99. Turetsky B.I., Calkins M.E., Light G.A., Olincy A., Radant A.D., Swerdlow N.R. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr. Bull. 2007, 33:69-94.
100. Umbricht D., Schmid L., Koller R., Vollenweider F.X., Hell D., Javitt D. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch. Gen. Psychiatry 2000, 57:1139-1147.
101. Umbricht D., Koller R., Vollenweider F.X., Schmid L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol. Psychiatry 2002, 51:400-406.
102. Viola F.C., Thorne J., Edmonds B., Schneider T., Eichele T., Debener S. Semi-automatic identification of independent components representing EEG artifact. Clin. Neurophysiol. 2009, 120:868-877.
103. Vollenweider F.X. Advances and pathophysiological models of hallucinogen drug actions in humans: a preamble to schizophrenia research. Pharmacopsychiatry 1998, 31:92-103.
104. Vollenweider F.X., Leenders K.L., Scharfetter C., Maguire P., Stadelmann O., Angst J. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F] fluorodeoxyglucose (FDG). Eur. Neuropsychopharmacol. 1997, 7:9-24.
105. Warbrick T., Mobascher A., Brinkmeyer J., Musso F., Richter N., Stoecker T., Fink G.R., Shah N.J., Winterer G. Single-trial P3 amplitude and latency informed event-related fMRI models yield different BOLD response patterns to a target detection task. NeuroImage 2009, 47:1532-1544.
106. Warbrick, T., Mobascher, A., Brinkmeyer, J., Musso, F., Stoecker, T., Shah, N.J., Fink, G., Winterer, G., submitted for publication. Using single trial EEG-fMRI to investigate nicotine effects on brain and behavioural responses to a visual oddball task.
107. Watson T.D., Petrakis I.L., Edgecombe J., Perrino A., Krystal J.H., Mathalon D.H. Modulation of the cortical processing of novel and target stimuli by drugs affecting glutamate and GABA neurotransmission. Int. J. Neuropsychopharmacol. 2009, 12:357-370.
108. Winterer G. Translational medicine: functional biomarkers for drug development of "cognitive enhancers" in schizophrenia. Neuropsychological Endophenotypes and Biomarkers 2009, I:57-86. Springer, Berlin. M. Ritsner (Ed.).
109. Winterer G., McCarley R.W. Electrophysiology of schizophrenia. Schizophrenia 2011, Blackwell Publishing, Oxford. D.R. Weinberger, P.J. Harrison (Eds.).
110. Winterer G., Weinberger D.R. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci. 2004, 27:683-690.
111. Winterer G., Mulert C., Mientus S., Gallinat J., Schlattmann P., Dorn H., Herrmann W.M. P300 and LORETA: comparison of normal subjects and schizophrenic patients. Brain Topogr. 2001, 13:299-313.
112. Wolf D.H., Turetsky B.I., Loughead J., Elliott M.A., Pratiwadi R., Gur R.E., Gur R.C. Auditory oddball fMRI in schizophrenia: association of negative symptoms with regional hypoactivation to novel distractors. Brain Imaging Behav. 2008, 2:132-145.
113. Woolrich M.W., Ripley B.D., Brady M., Smith S.M. Temporal autocorrelation in univariate linear modelling of fMRI data. NeuroImage 2001, 14:1370-1386.
114. Worsley K.J., Evans A.C., Marrett S., Neelin P. A three-dimensional statistical analysis for CBF activation studies in human brain. J. Cereb. Blood Flow Metab. 1992, 12:900-918.
115. Yonezawa Y., Kuroki T., Kawahara T., Tashiro N., Uchimura H. Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex. Eur. J. Pharmacol. 1998, 341:45-56.